Roche

e invite you... to save a life with early detection of cervical cancer

- Pap cytology does not uncover all disease^{1,2}
- Normal cytology does not always mean cancer free^{1,2}
- 99 % of cervical cancer is attributable to hrHPV genotypes^{3,4}

The cobas[®] HPV Test

KNOW THE RISK

I sample, I test, 3 results for confident risk stratification:

The **cobas**[®] **HPV** Test detects 14 high-risk genotypes with the ability to provide specific genotype results for HPV16 and HPV18.





For more information kindly refer to the following websites www.hpvl6andl8.com; www.sasog.co.za Ca

Call Centre: 0861 cobas HPV (262274)

References: 1. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675-683. **2.** Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622-629. **3.** Naucler P, Ryd W, Törnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101:88-99. **4.** Wallboomers JMM, Jacobs MV, Manos MM, et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.

Roche Diagnostics (Pty) Ltd, PO BOX 1927, Randburg, 2125. Tel: 011 5044600. www.roche.co.za